MONTRÉAL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Air Canada was named one of Canada's Best Diversity Employers for 2026, the eighth time in a decade the airline has received this recognition. "We’re proud to be recognized for our ongoing commitment to diversity, equity and inclusion. This award spotlights how our employees, resource groups, champions, leaders, and community partners work together to build a more fair, equitable, and inclusive future where everyone feels they belong," said Arielle Meloul-Wechsle ...

Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophyHOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in support of the ongoing BLA review SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that results from its Phase 3 HOPE-3 clini ...

New virtual agent capabilities reduce customer effort, prevent repeat contacts, and give service leaders confidence to scale automationWith 43% of consumers saying chatbots fail to resolve their issues, Zoom Virtual Agent 3.0 can help organizations close that gap SAN JOSE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Today Zoom Communications, Inc. (NASDAQ: ZM) unveiled Zoom Virtual Agent 3.0 (ZVA), the next evolution in agentic automation. ZVA introduces a new execution architecture and expanded AI capabiliti ...

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced its award-winning photographers, editors and operations staff will capture stunning imagery from the Milano Cortina 2026 Paralympic Winter Games. As the Official Photographic Agency of the International Paralympic Committee (IPC), Getty Images will deploy a team of 30 photograp ...

新加坡, Feb. 24, 2026 (GLOBE NEWSWIRE) -- 作為協助公司跨境發展的全球業務推動者，Enigmatig Limited (NYSE American: EGG)（「Enigmatig」或「公司」）今天公佈截至 2025 年 9 月 30 日止財政年度經審核的財務業績。 自公司在美國紐約證交所 (NYSE) 上市後，收入按年錄得 12.2% 可觀增長，毛利率更躍升至 68.8%，整體財務狀況亦更為穩健。 公司同時宣佈，已向美國證券交易委員會 (U.S. Securities and Exchange Commission) 提交了截至 2025 年 9 月 30 日止財政年度的 20-F 表格年度報告。 2025 財政年度的財務焦點 ●企業服務總收入增長 12.2%，由 2024 財政年度的 400 萬美元增至 2025 財政年度的 450 萬美元。●銷售成本由 2024 財政年度的 130 萬美元，增至 2025 財政年度的 140 萬美元。●毛利增長 14.9%，由 2024 財政年度的 270 萬美元上升至 2025 財政年度的 310 萬美元。●2025 財政年度營運利潤 ...

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep. This new relationship supports OneMedNet’s continued focus on expanding its base of subscri ...

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Enphase Energy, Inc. (NASDAQ: ENPH) (“Enphase” or the “Company”) on behalf of investors who purchased or otherwise acquired Enphase securities during the period from April 22, 2025 through October 28, 2025 (the “Class Period”). Investor Deadline: Investors who purchased Enphase securities during the Class Period may, no later than April 20, 2026, seek ...

Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technologyNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi ...

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy for non-small cell lung cancer (NSCLC) First and only direct telomere-targeting anticancer agent in clinical development anywhere MAIA CEO details development pipeline in letter to shareholders CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, ...

CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 9 ...